Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2017 Nov 15;17(1):26–38. doi: 10.1158/1535-7163.MCT-17-0580

Figure 1. Effect of MI-503 menin-MLL inhibitor on HCC cell lines growth.

Figure 1

A. MEN1 expression in normal versus tumor liver cells based on the analysis of the Oncomine datasets (30). B. Growth curves demonstrating the effect of MI-503 on cell growth in HepG2 cells. Viable cells were counted at days: 3, 6, 9, 13. Data are normalized to DMSO treated cells and represent mean of duplicates ± SD. C. MTT cell viability assay performed in HCC cell lines after 12 days of treatment with MI-503. Data are normalized to the DMSO treated cells and represent mean of quadruplicates ± SD. D. MTT cell viability assay performed for MI-503 in normal adipose-derived mesenchymal stem cells, ASC52. Data are normalized to the DMSO treated cells and represent mean of quadruplicates ± SD. E. Results from the Cellular Thermal Shift Assay (CETSA) performed in HepG2 cells. Detection of menin and GAPDH is shown on the SDS-PAGE gel. MI-503 was used at 2 μM.